News tagged ‘Melanoma’ clear
- A duo of drugs can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase I clinical trial led by Dana-Farber investigators.
- Scientists at Dana-Farber demonstrate that it’s possible, early in a tumor’s growth, to identify cancer genes that endow the tumor with the ability to metastasize. This is an important step toward developing prognostic tests for identifying early-stage tumors that are likely to spread and can be treated accordingly.
Tags: BasicResearch, Melanoma
- ABC News' Sam Donaldson shared his experience as a melanoma patient during his keynote speech at the Dana-Farber Cancer Institute Joint Visiting Committee Symposium dinner Nov. 15.
- It's still possible to get too much sun exposure in winter. Dana-Farber's skin cancer specialists explain the dangers and offer sun safety tips to help you protect your skin while enjoying outdoor winter activities.
Tags: Melanoma, Prevention, SkinCancer
- Scientists from Dana-Farber and the Broad Institute have sequenced 25 melanoma tumors and confirmed the long-held suspicion that chronic sun exposure plays a role in skin cancer.
Tags: Genomics, Melanoma
- A clinical trial for advanced melanoma caused growths to recede or stabilize in half of the participants by blocking a protein interaction that prevents T cells from attacking cancerous cells, reports lead author Stephen Hodi, MD.
Tags: ImmuneSystem, Melanoma
- Dana-Farber researchers are studying melanoma tumors' microenvironments to better understand how some melanoma continue to grow and survive despite the presence of anti-cancer drugs.
Tags: BasicResearch, Genomics, Melanoma
- Dana-Farber and Broad Institute researchers have identified two mutations that collectively occur in 71 percent of malignant melanoma tumors. These highly "recurrent" mutations may be the most common mutations in melanoma cells found to date.
Tags: Genomics, Melanoma
- Dana-Farber researchers found that combining the immune stimulator GM-CSF with the antibody drug ipilimumab prolonged survival in patients with metastatic melanoma and reduced the incidence of the most serious side effects.
- Dana-Farber researchers found that in patients with advanced melanoma using the immunotherapy ipilimumab, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in the blood was associated with a poorer response, suggesting that combining immunotherapy with VEGF inhibitors may be a potential option for these patients.
Tags: Melanoma, SkinCancer, Immunotherapy
Showing 11-20 of 21 items